Further, the combined and relatively pitiable free cash reserve of $4.9 billion will get wiped out 4 times over, if Bayer were to go through this deal. Rightly so, S&P’s rating has already put Bayer on ‘Credit watch with negative implications’ saying that the acquisition could “deteriorate credit quality of the resulting group.” For Merck, the death knell was sounded in its killer drug Vioxx. And for Bayer? Of course, in the killer company, Schering!
For Complete IIPM-Article, Click IIPM-B School
Source IIPM-Editorial,2006
For Complete IIPM-Article, Click IIPM-B School
Source IIPM-Editorial,2006
